Replicel Life Sciences
401 West Georgia Street
61 articles with Replicel Life Sciences
A paper entitled, "Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study", has been published summarizing the data from RepliCel's clinical trial of RCS-01
RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China
YOFOTO Health Now Commissioning its Manufacturing Facility in Preparation for Technology Transfer of Skin and Tendon Product Manufacturing and Applications for Clinical Trials
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector
Management strengthens its commitment to a successful upcoming market launch of RepliCel's dermal injector and consumables product line by addition of Damien King
Tendon Regeneration, Skin Rejuvenation and Dermal Injector Patents Granted in the United States, Europe, South Africa, Hong Kong, China, and Japan
YOFOTO (China) Health Announces Initiation of Facility Build-Out, New Hires, and Preparation to Submit Applications to China's Regulators
Next-stage trials in Japan present market launch opportunities for RepliCel's skin and tendon products
With a new strategic plan, RepliCel prioritizes focus on commercial revenue
Appointment of Dr. Goessens-Rueck strengthens management team and fulfils commitment to promote female leadership in biotech
The National Sciences and Engineering Research Council of Canada has funded a University of Victoria project aimed at collaborating with RepliCel to optimize cell culture and manufacturing technologies
RepliCel Life Sciences Inc. announces that its board of directors has appointed Simon Ma as the Chief Financial Officer of the Company.
Partnership and Investment Fuel Plans for Upcoming Advancements
YOFOTO (China) Health and RepliCel Life Sciences finalize investment and commence collaboration activity in Greater China
YOFOTO (China) Health and RepliCel Life Sciences now cleared to close investment transaction and commence collaboration activity in Greater China
RepliCel Life Sciences Inc. is pleased to announce it now has a new Binding Term Sheet (the "Term Sheet") with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") which both parties believe represents a stronger deal for both sides and positions them to finalize the transaction in the very near-term.
Replicel Life Sciences is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler.
Replicel Life Sciences is pleased to announce it has signed a Binding Term Sheet with YOFOTO to form a strategic partnership in Greater China.
Replicel Life Sciences Showcases First Fully-Functional Prototypes Of Its Next-Generation Dermal Injector